STOCK TITAN

New medial stabilized insert for Smith+Nephew’s LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Smith+Nephew (NYSE:SNN) has introduced a new medial stabilized insert for its LEGION Total Knee System. The innovation comes as medial stabilized inserts have seen significant growth, increasing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023. The new design features a larger anterior medial lip and medial pivot kinematics to maintain stability, similar to natural knee movement. The system can be used with or without the Posterior Cruciate Ligament, offering greater procedural efficiency and potentially reducing operating time. The LEGION TKS has over 20 years of clinical success, and this new insert supports both LEGION CONCELOC Cementless and LEGION Cemented Total Knee Systems. The product is currently available in the US on a limited basis, with full commercial release planned for later in 2025 and Canadian introduction in 2026.
Smith+Nephew (NYSE:SNN) ha introdotto un nuovo inserto stabilizzato medialmente per il suo sistema LEGION Total Knee. Questa innovazione arriva in un momento in cui gli inserti stabilizzati medialmente hanno registrato una crescita significativa, passando dal 4% delle procedure di artroplastica totale del ginocchio nel 2018 al 32% nel 2023. Il nuovo design presenta un labbro mediale anteriore più ampio e una cinematica a pivot mediale per garantire stabilità, simile al movimento naturale del ginocchio. Il sistema può essere utilizzato con o senza il legamento crociato posteriore, offrendo maggiore efficienza procedurale e potenzialmente riducendo i tempi operatori. Il LEGION TKS vanta oltre 20 anni di successo clinico, e questo nuovo inserto supporta sia i sistemi LEGION CONCELOC Cementless sia LEGION Cemented Total Knee. Il prodotto è attualmente disponibile negli Stati Uniti in quantità limitate, con un lancio commerciale completo previsto per la fine del 2025 e l'introduzione in Canada nel 2026.
Smith+Nephew (NYSE:SNN) ha presentado un nuevo inserto estabilizado medial para su sistema LEGION Total Knee. Esta innovación llega en un momento en que los insertos estabilizados medialmente han experimentado un crecimiento significativo, aumentando del 4% de los procedimientos de artroplastia total de rodilla en 2018 al 32% en 2023. El nuevo diseño cuenta con un labio medial anterior más grande y una cinemática de pivote medial para mantener la estabilidad, similar al movimiento natural de la rodilla. El sistema puede usarse con o sin el ligamento cruzado posterior, ofreciendo mayor eficiencia en el procedimiento y potencialmente reduciendo el tiempo quirúrgico. El LEGION TKS tiene más de 20 años de éxito clínico, y este nuevo inserto es compatible tanto con los sistemas LEGION CONCELOC Cementless como LEGION Cemented Total Knee. El producto está disponible actualmente en EE.UU. de forma limitada, con un lanzamiento comercial completo previsto para finales de 2025 y su introducción en Canadá en 2026.
Smith+Nephew(NYSE:SNN)는 LEGION Total Knee 시스템용 새로운 내측 안정화 인서트를 출시했습니다. 이 혁신은 내측 안정화 인서트가 2018년 전체 무릎 관절 성형술의 4%에서 2023년 32%로 크게 증가하는 추세에 맞춰 나왔습니다. 새로운 디자인은 더 큰 전방 내측 립과 내측 피벗 운동학을 특징으로 하여 자연스러운 무릎 움직임과 유사한 안정성을 유지합니다. 이 시스템은 후방 십자인대 유무에 관계없이 사용할 수 있어 시술 효율성을 높이고 수술 시간을 줄일 수 있습니다. LEGION TKS는 20년 이상의 임상 성공을 자랑하며, 이 새로운 인서트는 LEGION CONCELOC Cementless 및 LEGION Cemented Total Knee 시스템 모두를 지원합니다. 이 제품은 현재 미국에서 제한적으로 제공되며, 2025년 말에 전면 상업 출시 예정이고 2026년에는 캐나다에 도입될 예정입니다.
Smith+Nephew (NYSE:SNN) a lancé un nouvel insert stabilisé médial pour son système LEGION Total Knee. Cette innovation intervient alors que les inserts stabilisés médialement ont connu une croissance significative, passant de 4 % des procédures d'arthroplastie totale du genou en 2018 à 32 % en 2023. Le nouveau design comporte une lèvre médiale antérieure plus large et une cinématique à pivot médial pour maintenir la stabilité, similaire au mouvement naturel du genou. Le système peut être utilisé avec ou sans le ligament croisé postérieur, offrant une plus grande efficacité procédurale et pouvant réduire le temps opératoire. Le LEGION TKS bénéficie de plus de 20 ans de succès clinique, et ce nouvel insert prend en charge les systèmes LEGION CONCELOC Cementless et LEGION Cemented Total Knee. Le produit est actuellement disponible aux États-Unis en quantité limitée, avec un lancement commercial complet prévu pour fin 2025 et une introduction au Canada en 2026.
Smith+Nephew (NYSE:SNN) hat einen neuen medial stabilisierten Einsatz für sein LEGION Total Knee System vorgestellt. Diese Innovation kommt zu einem Zeitpunkt, an dem medial stabilisierte Einsätze ein deutliches Wachstum verzeichnen, von 4 % der Total-Knie-Arthroplastik-Verfahren im Jahr 2018 auf 32 % im Jahr 2023. Das neue Design verfügt über eine größere vordere mediale Lippe und mediale Pivot-Kinematik, um Stabilität ähnlich der natürlichen Kniebewegung zu gewährleisten. Das System kann mit oder ohne das hintere Kreuzband verwendet werden, was eine größere Verfahrenseffizienz ermöglicht und die Operationszeit möglicherweise verkürzt. Das LEGION TKS kann auf über 20 Jahre klinischen Erfolg zurückblicken, und dieser neue Einsatz unterstützt sowohl das LEGION CONCELOC Cementless als auch das LEGION Cemented Total Knee System. Das Produkt ist derzeit in den USA in begrenztem Umfang erhältlich, mit einer vollständigen Markteinführung für Ende 2025 und einer Einführung in Kanada im Jahr 2026 geplant.
Positive
  • Significant market adoption growth with medial stabilized inserts increasing from 4% to 32% of procedures (2018-2023)
  • Greater procedural efficiency and potential reduction in operating time
  • Compatible with both cemented and cementless systems
  • 20+ years of clinical success backing the LEGION platform
  • Flexibility to be used with or without Posterior Cruciate Ligament
Negative
  • Limited availability in US market initially
  • Delayed launch in Canada until 2026

Insights

Smith+Nephew launches strategic knee insert aligned with fast-growing market trend, potentially strengthening their competitive position in the $8B+ knee replacement market.

Smith+Nephew's new medial stabilized insert for their LEGION Total Knee System represents a significant strategic alignment with rapidly evolving market preferences. The dramatic increase in medial stabilized designs—from just 4% of total knee arthroplasties in 2018 to 32% in 2023—signals a major shift in surgical approach that S+N is now positioned to capitalize on.

This product enhancement offers three key clinical and operational advantages: First, it provides more natural knee kinematics through its medial pivot design, potentially improving patient outcomes and satisfaction. Second, it allows for more bone conservation by enabling use with Cruciate Retaining femoral designs rather than requiring Posterior Stabilized components. Third, it may reduce operating room time and procedural complexity by eliminating steps, creating efficiency opportunities for healthcare facilities.

The timing is particularly strategic as the orthopedic market increasingly favors both porous fixation technologies and kinematically advanced solutions. By integrating this insert with their existing LEGION portfolio (which includes both cemented and cementless CONCELOC options), Smith+Nephew strengthens their competitive positioning in the total knee replacement market.

While currently available on a limited basis in the US with full commercialization later in 2025, followed by Canada in 2026, this launch reinforces Smith+Nephew's commitment to innovation in their established knee replacement franchise, which has demonstrated over 20 years of clinical performance. This product enhancement should help S+N better compete against major orthopedic rivals like Stryker, Zimmer Biomet, and DePuy Synthes in the evolving knee replacement landscape.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1

With the ability to be used with or without the Posterior Cruciate Ligament (PCL), procedural trends are moving away from Posterior Stabilized (PS) design types to more bone-conservative Cruciate Retaining (CR) femoral designs. The reduction of operating steps also creates the potential for greater efficiency and shorter time in the OR for both surgeon and patient.2 

The medial stabilized design aims to maintain stability with a larger anterior medial lip and medial pivot kinematics similar to the natural knee.

“We’re entering an exciting era in knee replacement, driven by the momentum of personalized medicine and an influx of innovative approaches,” said Dr. Steve McDonald, Chief of Orthopaedics and Chief of Surgery, at London Health Sciences Centre in London, Ontario. “With US registry data now showing that one in three total knees utilize a medial stabilized design, it’s clear that surgeons are increasingly turning to solutions that offer more natural kinematics and higher patient satisfaction. The LEGION Medial Stabilized TKS stands out in this space - offering a powerful combination of medial stabilized kinematics, advanced porous fixation, integration with technologies like the CORI Surgical System, and a strong clinical legacy. It’s an ideal solution for surgeons looking to align with the principles of personalized care.”


The LEGION TKS has demonstrated more than 20 years of clinical success,3 with the new medial stabilized insert adding a modern design to align with rapidly growing market trends. The LEGION Medial Stabilized TKS is the latest addition to the LEGION portfolio supporting both the LEGION CONCELOC Cementless and LEGION Cemented Total Knee Systems.

“LEGION Medial Stabilized TKS is the latest evolution of the trusted LEGION brand - a platform backed by over 20 years of performance and innovation,” said Craig Gaffin, President, Global Orthopaedics for Smith+Nephew. “As market demand for porous and kinematically advanced knee solutions continues to grow, we believe this addition will elevate the LEGION portfolio even further, enabling us to better meet the evolving needs of patients and surgeons alike.”

The medial stabilized insert for LEGION TKS is available in the US on a limited basis, with a full commercial release later in 2025. The system will also be introduced in Canada in 2026. To hear more from Dr. MacDonald and Craig Gaffin, please visit here.

 - ends -

 

Enquiries

Media 
David Snyder+1 978-749-1440
Smith+Nephew

 

 
 

References

  1. American Joint Replacement Registry (AJRR) 2024 Annual Report.
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC12089135/#s4
  3. Victor J, Ghijselings S, Tajdar F, et al. Total knee arthroplasty at 15-17 years: does implant design affect outcome? Int Orthop. 2014;38(2):235-241.

 

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 17,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in around 100 countries, and generated annual sales of $5.8 billion in 2024. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

 

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.


FAQ

What is the new feature announced for Smith+Nephew's LEGION Total Knee System?

Smith+Nephew announced a new medial stabilized insert for its LEGION Total Knee System, featuring a larger anterior medial lip and medial pivot kinematics for improved stability.

How has the adoption of medial stabilized inserts grown in recent years?

Medial stabilized inserts have grown significantly from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.

When will SNN's new LEGION Medial Stabilized TKS be fully available?

The system is currently available in the US on a limited basis, with full commercial release planned for later in 2025 and Canadian introduction in 2026.

What are the key benefits of Smith+Nephew's new medial stabilized insert?

The key benefits include improved stability, natural knee-like kinematics, greater procedural efficiency, shorter operating time, and compatibility with both cemented and cementless systems.

How long has the LEGION Total Knee System been in clinical use?

The LEGION Total Knee System has demonstrated more than 20 years of clinical success.
Smith & Nephew

NYSE:SNN

SNN Rankings

SNN Latest News

SNN Stock Data

12.61B
437.85M
0.03%
8.13%
0.37%
Medical Devices
Healthcare
Link
United Kingdom
Watford